Gene Research
Tumor stroma hypoxia is a viable target for cancer gene therapy
Published in Gene Therapy Weekly, August 18th, 2005
"Deregulated tumor growth and neovascularization result in an inadequate tumor blood supply, leading to areas of chronic hypoxia and necrosis. Irregular vascular structure and abnormal tumor physiology also cause erratic blood flow in tumor vessels," scientists in England report.
"We reasoned that tumor stroma, including vascular endothelial cells, would consequently experience transient hypoxia that may allow transcriptional targeting as part of an antivascular gene therapy approach to cancer," said N. Ingram and colleagues, Institute for Cancer Research.
"To...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-08-18)
More Articles from Gene Therapy Weekly
- Enzymology
Nitric oxide synthase II repels metastasis despite upregulated angiogenesis - Gene Research
Uniform controls back the integrity of gene silencing approaches - Head & Neck Cancer
Transfected p16 rebuffs salivary cancer cell proliferation - Liver Cancer
Hepatocyte growth factor gene therapy impedes hepatoma cell proliferation - Stem Cell Research
Nonviral vectors fuel RNA interference in human mesenchymal stem cells - Alzheimer Disease
New findings in the area of Alzheimer disease described - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
